Products specifications
|
Species
|
Human
|
|
Format
|
96T
|
|
Sample Type
|
Tissue homogenates, cell lysates and other biological fluids
|
|
Assay Length
|
4.5 h
|
|
Detection Range
|
0.14-100ng/mL The standard curve concentrations used for the CLIA’s were 100ng/mL, 33.33ng/mL, 11.11ng/mL, 3.7ng/mL, 1.23ng/mL, 0.41ng/mL, 0.14ng/mL
|
|
Sensitivity
|
0.06ng/mL
|
|
Specificity
|
This assay has high sensitivity and excellent specificity for detection of B-Cell Leukemia/Lymphoma 2 (Bcl2).
No significant cross-reactivity or interference between B-Cell Leukemia/Lymphoma 2 (Bcl2) and analogues was observed.
|
|
Intra-Assay Precision
|
<10%
|
|
Inter-Assay Precision
|
<12%
|
|
Storage Temperature
|
-20 °C
|
|
Shipping Conditions
|
2-8 °C
|
|
Handling Instruction
|
The activity loss rate (stability) of this kit is less than 5% within the expiration date under appropriate storage conditions. To minimize extra influence on the stability, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. When not in use, kit components should be refrigerated. All reagents should be brought to room temperature before use. It is recommended that all standards, controls, and samples be run in duplicate. Do not mix or interchange different reagent lots from various kit lots.
|
|
Test Principle
|
The microtiter plate provided in this kit has been pre-coated with an antigen. Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated secondary antibody. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the B-Cell Leukemia/Lymphoma 2 (Bcl2) level in the sample or standard.
|
|
Notes
|
All kits are custom made on-demand. Please allow 10-15 working days for production and 2-3 days for shipment.
|
|
Legal Information
|
Marketed under license from USCN Life Science Inc.
|
| Reagents | Quantity |
| Pre-coated, ready to use 96-well strip plate | 1 |
| Standard | 2 |
| Detection Reagent A | 1×120µL |
| Detection Reagent B | 1×120µL |
| Substrate A | 1×10mL |
| Wash Buffer (30 × concentrate) | 1×20mL |
| Plate sealer for 96 wells | 4 |
| Standard Diluent | 1×20mL |
| Assay Diluent A | 1×12mL |
| Assay Diluent B | 1×12mL |
| Substrate B | 1×2mL |
| Instruction manual | 1 |
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of B-Cell Leukemia/Lymphoma 2 (Bcl2) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 88-104% | 96-104% | 82-102% | 97-104% |
| EDTA plasma(n=5) | 86-101% | 95-102% | 89-97% | 78-94% |
| heparin plasma(n=5) | 90-98% | 97-104% | 91-98% | 79-90% |
Matrices listed below were spiked with certain level of recombinant B-Cell Leukemia/Lymphoma 2 (Bcl2) and the recovery rates were calculated by comparing the measured value to the expected amount of B-Cell Leukemia/Lymphoma 2 (Bcl2) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 97-105 | 101 |
| EDTA plasma(n=5) | 82-104 | 101 |
| heparin plasma(n=5) | 88-97 | 93 |